X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (241) 241
humans (220) 220
gliclazide (162) 162
diabetes mellitus, type 2 - drug therapy (161) 161
male (151) 151
female (133) 133
middle aged (122) 122
endocrinology & metabolism (115) 115
hypoglycemic agents - therapeutic use (108) 108
gliclazide - therapeutic use (105) 105
aged (101) 101
hypoglycemic agents - adverse effects (97) 97
gliclazide - adverse effects (95) 95
type 2 diabetes (88) 88
diabetes (74) 74
diabetes mellitus, type 2 - blood (64) 64
pharmacology & pharmacy (58) 58
metformin (56) 56
hypoglycemic agents - administration & dosage (55) 55
adult (53) 53
blood glucose - metabolism (50) 50
insulin (50) 50
glucose (48) 48
sulfonylurea compounds - therapeutic use (47) 47
gliclazide - administration & dosage (46) 46
mellitus (46) 46
sulfonylurea compounds - adverse effects (46) 46
glibenclamide (45) 45
hypoglycemic agents (40) 40
diabetes mellitus (39) 39
hypoglycemia (38) 38
hypoglycemia - chemically induced (38) 38
animals (37) 37
treatment outcome (37) 37
drug therapy, combination (36) 36
glycated hemoglobin a - metabolism (36) 36
glycemic control (36) 36
mortality (36) 36
risk factors (36) 36
sulfonylureas (36) 36
metformin - therapeutic use (35) 35
blood glucose - drug effects (33) 33
sulfonylurea (31) 31
diabetes therapy (30) 30
analysis (29) 29
care and treatment (29) 29
type 2 diabetes mellitus (29) 29
drug therapy (28) 28
gliclazide - pharmacology (28) 28
glimepiride (28) 28
therapy (28) 28
diabetes mellitus, type 2 - complications (27) 27
thiazolidinediones - therapeutic use (27) 27
hypoglycemic agents - pharmacology (25) 25
pioglitazone (25) 25
double-blind method (24) 24
medicine & public health (24) 24
risk (24) 24
glycated hemoglobin a - analysis (23) 23
research (23) 23
efficacy (22) 22
glyburide - therapeutic use (22) 22
administration, oral (20) 20
glyburide - adverse effects (20) 20
internal medicine (20) 20
metformin - administration & dosage (20) 20
metformin - adverse effects (20) 20
blood glucose - analysis (19) 19
complications (19) 19
double-blind (19) 19
drugs (19) 19
time factors (19) 19
rats (18) 18
sulfonylurea compounds - administration & dosage (18) 18
aged, 80 and over (17) 17
diabetes mellitus - drug therapy (17) 17
health aspects (17) 17
cardiovascular disease (16) 16
clinical trials (16) 16
dextrose (16) 16
diabetes mellitus, type 2 - physiopathology (16) 16
hyperglycemia (16) 16
medicine, general & internal (16) 16
blood sugar (15) 15
cohort studies (15) 15
follow-up studies (15) 15
pharmacokinetics (15) 15
pharmacology/toxicology (15) 15
physiological aspects (15) 15
retrospective studies (15) 15
diabetes mellitus, type 2 - metabolism (14) 14
dosage and administration (14) 14
dose-response relationship, drug (14) 14
drug combinations (14) 14
fasting (14) 14
glycosylated hemoglobin (14) 14
insulin - blood (14) 14
metabolism (14) 14
oxidative stress (14) 14
rosiglitazone (14) 14
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (275) 275
French (10) 10
German (3) 3
Chinese (1) 1
Dutch (1) 1
Italian (1) 1
Japanese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetologia, ISSN 0012-186X, 12/2016, Volume 59, Issue 12, pp. 2603–2612 - 2612
Journal Article
Hypertension, ISSN 0194-911X, 02/2014, Volume 63, Issue 2, pp. 259 - 264
Journal Article
Diabetes Care, ISSN 0149-5992, 11/2017, Volume 40, Issue 11, pp. 1506 - 1513
OBJECTIVE Sulfonylureas have been associated with an increased risk of cardiovascular adverse events and hypoglycemia, but it is unclear if these risks vary... 
MORTALITY | VASCULAR COMPLICATIONS | METAANALYSIS | DRUGS | ENDOCRINOLOGY & METABOLISM | AGENTS | DEATH | GLIMEPIRIDE | GLYBURIDE | PRACTICE RESEARCH DATABASE | Myocardial Infarction - mortality | Tolbutamide - administration & dosage | Follow-Up Studies | Glipizide - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glipizide - adverse effects | Hypoglycemia - mortality | Male | Gliclazide - administration & dosage | Incidence | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Cardiovascular Diseases - mortality | Female | Sulfonylurea Compounds - administration & dosage | Stroke - mortality | Gliclazide - adverse effects | Body Mass Index | Tolbutamide - adverse effects | Risk Factors | Proportional Hazards Models | Pancreas - drug effects | Pancreas - metabolism | Sulfonylurea Compounds - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | United Kingdom - epidemiology | Cohort Studies | Complications and side effects | Care and treatment | Dosage and administration | Diabetes | Cardiovascular diseases | Hypoglycemia | Hypoglycemic sulfonylureas | Sulfonylurea compounds | Risk factors | Myocardial infarction | Cerebral infarction | Stroke | Initiators | Mortality | Diabetes mellitus | Tolbutamide | Health risks | Cardiovascular disease | Risk | Hazards | Pharmacology | Statistics | Side effects | Statistical models | Ischemia | Sulfonylurea | Infarction | Research design | Pancreas | Index Medicus
Journal Article
Diabetic Medicine, ISSN 0742-3071, 2010, Volume 27, Issue 3, pp. 318 - 326
P>Aim To demonstrate non-inferiority of vildagliptin compared with gliclazide, as an add-on therapy, in patients with Type 2 diabetes inadequately controlled... 
Type 2 diabetes | Vildaglitpin | Gliclazide | Glycated haemoglobin | Metformin | GLYCEMIC CONTROL | GLUCOSE CONTROL | MILD HYPERGLYCEMIA | metformin | TREATED PATIENTS | MELLITUS | vildaglitpin | gliclazide | DRUG-NAIVE PATIENTS | INSULIN | THERAPY | ENDOCRINOLOGY & METABOLISM | CLINICAL-IMPLICATIONS | DOUBLE-BLIND | glycated haemoglobin | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Gliclazide - administration & dosage | Metformin - adverse effects | Pyrrolidines - therapeutic use | Nitriles - administration & dosage | Young Adult | Gliclazide - therapeutic use | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Drug Therapy, Combination | Gliclazide - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Diabetes Mellitus, Type 2 - blood | Adolescent | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Nitriles - therapeutic use | Complications and side effects | Medical research | Care and treatment | Medicine, Experimental | Glycosylated hemoglobin | Hypoglycemic agents | Glucose | Comparative analysis | Dextrose | Diabetes therapy | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2010, Volume 363, Issue 15, pp. 1410 - 1418
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 24, pp. 2560 - 2572
Journal Article
Current Medical Research & Opinion, ISSN 0300-7995, 07/2011, Volume 27, Issue 7, pp. 1367 - 1374
Journal Article
Vascular Health and Risk Management, ISSN 1176-6344, 2014, Volume 10, pp. 319 - 326
Several observational studies were conducted with vildagliptin in patients with type 2 diabetes mellitus (T2DM) fasting during Ramadan, showing significantly... 
Incretin | Dipeptidyl peptidase 4 | Fasting | Type 2 diabetes mellitus | Hypoglycemia | Ramadan | Telephone | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Body Weight - drug effects | Pyrrolidines - adverse effects | Male | Pyrrolidines - therapeutic use | Middle East | Gliclazide - therapeutic use | Time Factors | Fasting - blood | Counseling | Glycated Hemoglobin A | Adamantane - therapeutic use | Female | Hypoglycemia - blood | Hypoglycemia - chemically induced | Gliclazide - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Office Visits | Europe | Treatment Outcome | Biomarkers - blood | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - blood | Medication Adherence | Islam | Asia | Religion and Medicine | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Nitriles - therapeutic use | Type 2 diabetes | Physician and patient | Religious aspects | Patient outcomes | Gliclazide | Dosage and administration | Drug therapy | Health aspects | Muslims | Clinical trials | Insulin resistance | Glucose | Diabetes | Patients | Index Medicus | type 2 diabetes mellitus | fasting | dipeptidyl peptidase 4 | incretin | hypoglycemia
Journal Article